
Sign up to save your podcasts
Or


At the 2025 American Urological Association (AUA 2025) Meeting in Las Vegas, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talked to Dr. Neal Shore (US) about the CREST study results: Sasanlimab in combination with bacillus calmette-guérin (BCG) improves event-free survival (EFS) versus bacillus calmette-guérin as standard of care in high-risk non- muscle-invasive bladder cancer (NMIBC).
Dr. Shore explains the study rational, the results of the study, and the take home messages he presented during the meeting.
By European Association of Urology3.7
33 ratings
At the 2025 American Urological Association (AUA 2025) Meeting in Las Vegas, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talked to Dr. Neal Shore (US) about the CREST study results: Sasanlimab in combination with bacillus calmette-guérin (BCG) improves event-free survival (EFS) versus bacillus calmette-guérin as standard of care in high-risk non- muscle-invasive bladder cancer (NMIBC).
Dr. Shore explains the study rational, the results of the study, and the take home messages he presented during the meeting.

43,741 Listeners

318 Listeners

499 Listeners

1,423 Listeners

2,445 Listeners

17 Listeners

1 Listeners

144 Listeners

57 Listeners

2 Listeners

3,658 Listeners

53 Listeners

1,675 Listeners

0 Listeners

3 Listeners